Technology
Health
Biotechnology

Denali Therapeutics

$19.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.27 (1.38%) Today
+$0.27 (1.38%) Today

Why Robinhood?

You can buy or sell DNLI and other stocks, options, ETFs, and crypto commission-free!

About

Denali Therapeutics Inc. Common Stock, also called Denali Therapeutics, is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Read More Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Employees
179
Headquarters
San Francisco, California
Founded
2013
Market Cap
1.84B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
403.38K
High Today
$19.72
Low Today
$19.29
Open Price
$19.48
Volume
10.01K
52 Week High
$25.05
52 Week Low
$12.32

Collections

Technology
Health
Biotechnology
Therapy
2017 IPO
US
North America

News

Simply Wall StMar 12

Is Denali Therapeutics Inc. (NASDAQ:DNLI) A Financially Strong Company?

Stocks with market capitalization between $2B and $10B, such as Denali Therapeutics Inc. (NASDAQ:DNLI) with a size of US$2.1b, do not attract as much attention from the investing community as do the small-caps and large-caps. However, history shows that overlooked mid-cap companies have performed better on a risk-adjusted manner than the smaller and larger segment of the market. Today we will look at DNLI’s financial liquidity and debt levels, which are strong indicators for whether the company can weather ...

196
MarketBeatMar 4

Stock Price, News, & Analysis for Denali Therapeutics

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibit...

47

Earnings

-$0.59
-$0.13
$0.33
$0.79
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
$0.79 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.